Bannerbild German Brest Group - Forschung

Übersicht über Kongressbeiträge von 2011

Mitglieder der German Breast Group präsentierten im Jahr 2011 folgende Beiträge auf internationalen Kongressen:

SABCS

de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Coleman R: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. Cancer Res 71(24 Suppl.): 96s, 2011
Möbus V, Diel IJ, Elling D, Harbeck N, Jackisch C, Thomssen C, Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller V, Lück HJ, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G for the GBG/AGO study groups: Gain study: A phase III trial to compare ETC vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer – 1st interim EFFICACY analysis. Cancer Res 71(24 Suppl.): 100s, 2011

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Michael Zahm D, Mehta K, Loibl S: Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – Results of the GeparTrio trial. Cancer Res 71(24 Suppl.): 103s, 2011

Huober J, Hanusch C, Fasching P, Rezai M, Eidtmann H, Kittel K, Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, Loibl S, Nekljudova V, Untch M von Minckwitz G for the GBG and AGO-B study groups: Neoadjuvant CHEMOTHERAPY of Paclitaxel with or Without Rad001 Results of the NON-Responder Part of The GEPARQUINTO study (GBG 44). Cancer Res 71(24 Suppl.): 105s, 2011

Loibl S, von Minckwitz G, Blohmer JU,Costa SD, Eidtmann H, Fasching P, Gerber B, Hilfrich J, HuoberJ , Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Untch M for the GBG and AGO-B study groups: pCR as surrogate in HER2-positive patients treated with trastuzumab - taking into account anti-HER2 treatment. Cancer Res 71(24 Suppl.): 111s, 2011

von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M for the GBG and AGO-B study groups: Local recurrence risk after neoadjuvant chemotherapy. Pooled analysis on 5477 breast cancer patients. Cancer Res 71(24 Suppl.): 142s, 2011

Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl H, Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann M, Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, Kronenwett R: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer. Cancer Res 71(24 Suppl.): 187s, 2011

Eidtmann H, Kittel K, Rezai M, Tesch H, Ulmer HU, Stirnberg S, Belau A, Mau C, Stickeler E, Schrader I, Fasching P, Salat C, Abdallah A, Holms F, Schwedler K, Nekljudova V, Loibl L, von Minckwitz G: Surgical complications from the GeparQuinto trial of patients receiving preoperative Bevacizumab. Cancer Res 71(24 Suppl.): 237s, 2011

Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Bundred N: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial. Cancer Res 71(24 Suppl.): 325s, 2011

Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp F, Fehm T, Schrader I, Uleer C, Kohls A, Stirnberg S, zu Eulenburg C, Untch M, Müller V: Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab – A Translational Project in the Neoadjuvant "Geparquinto" Trial. Cancer Res 71(24 Suppl.): 454s, 2011

von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion MJ, Ross G, Saini KS, Piccart-Gebhart M: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). Cancer Res 71(24 Suppl.): 602s, 2011

von Minckwitz G, Cortés J, Gligorov J, Marschner NW, Puglisi F, Vrdoljak E, Duenne A-A, Zielinski C: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC). Cancer Res 71(24 Suppl.): 621s, 2011

de la Haba HR, von Minckwitz G, Martín M, Morales S, Crespo C, Guerrero A, Antón A, Gil M, Muñoz M, Carrasco E, Rodríguez C, Porras I, Aktas B, Schoenegg W, Tio J, Mehta K, Loibl S, on behalf of GEICAM and GBG: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the LEA study. Cancer Res 71(24 Suppl.): 625s, 2011

ASCO Breast

von Minckwitz G, Darb-Esfahani S, Loibl S, Tesch H, Huober J, Solbach C, Holms F, Eidtmann H, Diedrich K, Just M, Clemens M, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). ASCO Breast 2011 (Poster)

Senologie

Maisch A, Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A, Barinoff J, Holms F, Thomssen C, Zahm D.M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G: Wiedereinsatz von Taxanen beim rezidivierten Brustkrebs von Patientinnen, die mit einer (neo-) adjuvanten Taxan-haltigen Chemotherapie behandelt wurden. Senologie 2011 (Poster)

ASCO

Loibl S, Bruey J, von Minckwitz G, Huober J, Press M.F, Darb-Esfahani S, Solbach C, Denkert C, Tesch H, Holms F, Fehm T, Mehta K, Untch M: Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 29: 2011 (suppl; abstr 530)

von Minckwitz G, Kaufmann M, Kuemmel S, Fasching P. A, Eiermann W, Blohmer J.U, Costa S.D, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J. B, Hanusch C. A, Konecny G. E, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M, GBG and AGO-B study groups: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 29: 2011 (suppl; abstr 1028)

Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P. A, Barinoff J, Holms F, Thomssen C, Zahm D. M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G, German breast group and AGO-B Study Group: Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. J Clin Oncol 29: 2011 (suppl; abstr 1055)

Conrad B, Harbeck N, von Minckwitz G, Wuellner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Loibl S, GBG/AGO-B study groups: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). J Clin Oncol 29: 2011 (suppl; abstr 1059)

Gerber B, Eidtmann H, Rezai M, Fasching P. A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C. A, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer J.U, Huober J.B, Hauschild M, Loibl S, Nekljudova V, Untch M, von Minckwitz G, GBG/AGO study groups: Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 29: 2011 (suppl; abstr 1006)

Wenners A. S, Mehta K, Loibl S, Park H, Arnold N, Hamann S, Weimer J, Ataseven B, Schem C, Khandan F, Thomssen C, Jonat W, Holzhausen H, von Minckwitz G, Denkert C, Bauer M: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 595)

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Hanker L. C, Sänger N, Holtrich U, Kaufmann M, Darb-Esfahani S, Nekljudova V, von Minckwitz G: Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 615)

Heitz F, Sinn B, Loibl S, du Bois A, Jackisch C, Kuemmel S, Denkert C, Barinoff J, Mehta K, von Minckwitz G, on behalf the GeparTrio trialists: Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. J Clin Oncol 29: 2011 (suppl; abstr 1069)

Budczies J, Denkert C, Mueller B, Brockmoeller S.F, Dietel M, Radke C, Loibl S, von Minckwitz G, Griffin J.L, Oresic M, Wohlgemut G, Fiehn O: Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. J Clin Oncol 29: 2011 (suppl; abstr 10514)

Denkert C, Kronenwett R, Loibl S, Nekljudova N, Darb-Esfahani S, Gerber B, Sinn B, Petry C, Bauerfeind I, Budczies J, Rezai M, Dietel M, Schrader I, Kunz G, von Minckwitz G, GBG and AGO-B study groups: RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. J Clin Oncol 29: 2011 (suppl; abstr 10526)

Kontakt

Lejla Valjevcic

Tel.: +4961027480418

Fax: +4961027480118

E-Mail: Pblctngbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd